Insider Buying: Pulse Biosciences (NASDAQ:PLSE) Director Purchases $12,999,987.77 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) Director Robert Duggan purchased 660,233 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the purchase, the director directly owned 48,211,433 shares in the company, valued at $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pulse Biosciences Price Performance

Shares of PLSE opened at $23.96 on Thursday. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $26.30. The stock has a market cap of $1.63 billion, a PE ratio of -21.78 and a beta of 1.63. The firm has a fifty day moving average price of $21.03 and a 200 day moving average price of $17.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.25 million. As a group, equities analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PLSE has been the topic of a number of recent research reports. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 20th. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of Pulse Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Argo Wealth Advisory LLC purchased a new stake in Pulse Biosciences in the 4th quarter valued at approximately $387,000. Russell Investments Group Ltd. boosted its stake in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Pulse Biosciences during the fourth quarter worth $244,000. Farther Finance Advisors LLC raised its position in Pulse Biosciences by 39.2% in the fourth quarter. Farther Finance Advisors LLC now owns 20,373 shares of the company’s stock worth $280,000 after acquiring an additional 5,734 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Pulse Biosciences by 99.0% in the third quarter. BNP Paribas Financial Markets now owns 3,480 shares of the company’s stock valued at $62,000 after acquiring an additional 1,731 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.